← ANALYST RATINGS · TIPRANKS
Olema Pharmaceuticals (OLMA): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $36.25, the highest $59.00, the lowest $16.00. The average is +450.9% from the last price of $6.58.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | +14.0% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $7.50 → $7.00−6.7% | Sell | +6.4% | Downgrade | 13.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $7.00−6.7% | Sell | +6.4% | Downgrade | 13.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.00−12.5% | Hold | +6.4% | Reiterated | 13.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.00−12.5% | Sell | +6.4% | Downgrade | 13.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | +14.0% | Reiterated | 07.10.26on TipRanks 05:05 | — | |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $36.00 | Buy | +447.1% | Reiterated | 21.09.26on TipRanks 06:35 | −3.5%next day +0.1% · 5 days −9.6% | ↗ |
| Sam Slutsky★★★★★★★★★★#35 · hits 55% · avg +49.4% | LifeSci Capital | $16.00 | Buy | +143.2% | Reiterated | 19.09.26on TipRanks Sep 21 02:05 | −3.5%next day +0.1% · 5 days −9.6% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $20.00 → $18.00−10.0% | Buy | +173.6% | Reiterated | 14.09.26on TipRanks 07:35 | +1.1%next day −4.5% · 5 days −8.3% | ↗ |
| Laura Prendergast★★★★★★★★★★#345 · hits 76% · avg +52.4% | Stifel Nicolaus | $48.00 → $30.00−37.5% | Buy | +355.9% | Reiterated | 14.09.26on TipRanks 07:35 | +1.1%next day −4.5% · 5 days −8.3% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | — | Buy | — | Reiterated | 14.09.26on TipRanks 06:15 | +1.1%next day −4.5% · 5 days −8.3% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $59.00 | Buy | +796.7% | Reiterated | 13.09.26on TipRanks 18:35 | +1.1%next day −4.5% · 5 days −8.3% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $40.00 | Buy | +507.9% | Reiterated | 20.08.26on TipRanks 07:15 | −2.8%next day −2.3% · 5 days −2.1% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 10.08.26on TipRanks Aug 11 02:45 | −0.9%next day −12.3% · 5 days −9.8% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $45.00 | Buy | +583.9% | Reiterated | 02.06.26on TipRanks Jun 4 22:25 | −16.0%next day −1.0% · 5 days +0.7% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $38.00 → $35.00−7.9% | Buy | +431.9% | Reiterated | 01.06.26on TipRanks 07:55 | −3.9%next day −16.0% · 5 days −19.1% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | — | Hold | — | Initiated | 26.03.26on TipRanks 16:20 | −1.5%next day −1.5% · 5 days +7.1% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $43.00 → $40.00−7.0% | Buy | +507.9% | Initiated | 19.03.26on TipRanks 05:25 | +3.0%next day −4.4% · 5 days −3.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Olema Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $33.17 at a price of $8.64 (+283.9%); now: $33.17 at $6.58 (+404.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 9 | 10 | 11 | 13 | 11 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.64 (from $-0.73 to $-0.50). Last quarter: $-0.61.
Best top-analyst consensus in the sector · Healthcare
About Olema Pharmaceuticals
- CEO: Sean Bohen
- Employees: 150
- 780 Brannan Street, San Francisco, CA, 94103, US
- www.olema.com
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗